1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6253551061B1DC84F85258417003836D7
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-patient-advocacy-2020-optimizing-partnerships-improve-access-boost-patient-voice?OpenDocument
18
19OpenDocument
2018.206.48.142
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Patient Advocacy

Patient Advocacy 2020: Optimizing Advocacy Partnerships to Improve Access & Boost Patient Voice

ID: 5561


Features:

21 Info Graphics

13 Data Graphics

250+ Metrics

8 Narratives


Pages/Slides: 43


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Optimizing Advocacy Partnerships to Improve Access & Boost Patient Voice"

STUDY OVERVIEW

Partnerships with patient advocacy groups are seen as an effective way to reach specific patient groups about new therapies and treatment options. Given their close relationship to patients, advocacy groups are critical partners for pharma - especially in therapeutic areas that are socially sensitive.

This research provides current benchmarks on the tools and tactics pharma organizations are using to create and maintain effective collaborations with patient advocacy groups. The study also reviews how pharma groups are measuring the performance of their advocacy role, and managing relationships with advocacy groups representing controversial disease states. The study also contains a chapter that contains qualitative data from respondents regarding advocacy collaboration. Leaders who oversee the advocacy function within pharma can use this study to compare their partnership approaches with their industry peers.


KEY TOPICS

  • Understanding the “Advocacy” landscape
  • Patient Advocacy Partner Coordination & Effectiveness
  • Developing & Optimizing Patient Advocacy Partnerships
  • Managing Relationships Within Controversial Disease States
  • Appendix - Qualitative Responses to Best Practices for Advocacy Collaboration

SAMPLE KEY METRICS
  • Metrics that are effective for measuring success of patient advocacy activities and relationships
  • Importance rating of patient advocacy collaborations at different lifecycles
  • Best approach to deploying advocacy grants/sponsorships for early stage support with advocacy groups
  • Most critical considerations when managing collaborations with advocacy groups regarding therapies with social stigma
  • Strategies or tactics most effective for minimizing opposition from special interest groups regarding a controversial therapy
SAMPLE KEY FINDING
  • Assessing the best tools to manage advocacy relationships: Transparency & authenticity is the key to effectively coordinate relationships with patient advocacy groups, according to 67% of the participants. Managing relationships with advocacy groups also benefits from clear roles and responsibilities. This can be achieved by conducting awareness campaigns across key stakeholders and designating roles and responsibilities. At least 45% of benchmark class gave “relationship ownership,” " awareness campaigns," and "role clarity" high effectiveness ranking.

METHODOLOGY

This study engaged 74 leaders supporting patient advocacy at 61 life sciences companies and organizations. More than 60% of participants are at the director/ senior director level. Nearly 65% of participants are from the United States.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Communications; Medical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Clinical Research; Research; Health Care; Laboratories


Companies Profiled:
AbbVie; Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; ApotheCom; Astellas; AveXis; AVROBIO; Baldwin Area Medical Center; Bayer; Biogen; BioMarin; Bionical Emas; Blue Earth Diagnostics; Bluebird Bio; Boehringer Ingelheim; Covance; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Forum Pharmaceuticals; Grifols; GlaxoSmithKline ; Genzyme; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Lundbeck; Mallinckrodt; Merck; Milestone Pharmaceuticals; MSD; Natera; NexGen Healthcare Communications; Novartis; Novo Nordisk; OTSUKA; Parkway Pantai; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Sanofi; Servier; Shire; Spark Therapeutics; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; Theravance; Tillotts Pharma; UCB Pharma; Ultragenyx; Wave Life Sciences; Zimmer Biomet; Zogenix; The Mexican Organization for Rare Disorders (OMER)

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.